Use of proteomic patterns in serum to identify ovarian cancer
- PMID: 11867112
- DOI: 10.1016/S0140-6736(02)07746-2
Use of proteomic patterns in serum to identify ovarian cancer
Abstract
Background: New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary.
Methods: Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary "training" set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders.
Findings: The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93--100), specificity of 95% (87--99), and positive predictive value of 94% (84--99).
Interpretation: These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.
Comment in
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):169; author reply 170-1. doi: 10.1016/S0140-6736(02)09387-X. Lancet. 2002. PMID: 12126842 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):169-70; author reply 170-1. doi: 10.1016/S0140-6736(02)09388-1. Lancet. 2002. PMID: 12126843 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):170; author reply 170-1. doi: 10.1016/S0140-6736(02)09389-3. Lancet. 2002. PMID: 12126844 No abstract available.
-
Proteomic patterns in serum and identification of ovarian cancer.Lancet. 2002 Jul 13;360(9327):170; author reply 170-1. doi: 10.1016/s0140-6736(02)09390-x. Lancet. 2002. PMID: 12126845 No abstract available.
-
Importance of disclosure of patent applications.Lancet. 2004 Aug 14-20;364(9434):577-8; author reply 578-9. doi: 10.1016/S0140-6736(04)16839-6. Lancet. 2004. PMID: 15313348 No abstract available.
-
Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit.Clin Chem. 2010 Oct;56(10):1641-2. doi: 10.1373/clinchem.2010.146142. Epub 2010 Jul 21. Clin Chem. 2010. PMID: 20660141 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical